Short Interest in Affimed (NASDAQ:AFMD) Decreases By 19.3%

Affimed (NASDAQ:AFMD) was the target of a large decline in short interest in the month of July. As of July 31st, there was short interest totalling 783,900 shares, a decline of 19.3% from the July 15th total of 971,500 shares. Currently, 6.0% of the shares of the company are sold short. Based on an average trading volume of 694,200 shares, the short-interest ratio is presently 1.1 days.

Analysts Set New Price Targets

AFMD has been the subject of several research reports. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Affimed in a research note on Thursday, June 13th. Laidlaw lifted their target price on shares of Affimed from $15.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, June 13th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $32.50.

Affimed Stock Performance

Shares of NASDAQ:AFMD traded up $0.03 during trading on Friday, hitting $3.98. 82,125 shares of the stock traded hands, compared to its average volume of 339,611. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.06 and a quick ratio of 3.06. The company has a fifty day moving average price of $5.30 and a two-hundred day moving average price of $5.41. Affimed has a 52-week low of $2.23 and a 52-week high of $8.95.

Affimed (NASDAQ:AFMD) last posted its earnings results on Wednesday, June 12th. The biopharmaceutical company reported ($1.38) earnings per share for the quarter, beating the consensus estimate of ($1.73) by $0.35. The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $1.76 million. Affimed had a negative net margin of 2,361.94% and a negative return on equity of 135.81%. On average, analysts predict that Affimed will post -3.6 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Affimed

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Choreo LLC purchased a new stake in Affimed in the 2nd quarter worth $54,000. EWA LLC acquired a new stake in Affimed during the 4th quarter worth $89,000. abrdn plc acquired a new stake in Affimed during the 4th quarter worth $130,000. Vestal Point Capital LP acquired a new stake in Affimed during the 4th quarter worth $341,000. Finally, BNP Paribas Financial Markets boosted its stake in Affimed by 39.9% during the 4th quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock worth $357,000 after purchasing an additional 163,162 shares during the last quarter. Hedge funds and other institutional investors own 30.82% of the company’s stock.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.